International Journal of Colorectal Disease

, Volume 25, Issue 3, pp 303–311 | Cite as

Functional analysis of LOXL2 in pancreatic carcinoma

  • Felix Rückert
  • Peer Joensson
  • Hans-Detlev Saeger
  • Robert Grützmann
  • Christian Pilarsky
Original Article
First Online:
Accepted:

Abstract

Objectives

Lysyl oxidase-like 2 (LOXL2) plays a part in epithelial–mesenchymal transition (EMT) by stabilizing the transcription factor SNAI1. Previous studies showed that LOXL2 is one of the most highly and specifically upregulated genes in pancreatic cancer. LOXL2 was also found to be strongly upregulated in the secretome of established pancreatic cancer cell lines. To get more insight into the aggressive growth and infiltrating nature of pancreatic cancer, we evaluated the functional role of LOXL2 in pancreatic cancer cells.

Methods

Gene inhibition by small interfering RNAs was used to silence LOXL2 in pancreatic cancer cell lines MiaPaCa-2 and Panc1. Cell death, proliferation, and morphology of transfected cells were determined. Cell characteristics under cell stress and gemcitabine treatment were analyzed. Gene expression analysis of transfected cells by DNA microarray was used to understand the processes of chemosensitization.

Results

Silencing of LOXL2 in pancreatic cancer cells resulted in an augmented sensitivity toward gemcitabine treatment, with significantly elevated cell death and reduced viable cells. However, transfection had no direct effect on morphology or growth pattern of Mia PaCa-2 and Panc1 cell lines. Gene expression analysis identified among others the transcription factor E2F5 as possible target of LOXL2.

Conclusions

Gene inhibition of the EMT regulatory gene LOXL2 resulted in a distinct sensitization toward gemcitabine. Additionally, gene expression analysis showed a role for LOXL2 in the regulation of different transcription factors associated with invasion and metastasis. Our results suggest that the improved response toward chemotherapy in LOLX2-silenced pancreatic cancer cells is possibly mediated by the transcription factor E2F5.

Keywords

LOXL2 Pancreatic cancer Epithelial–mesenchymal transition Gene expression analysis E2F5 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Lowenfels AB, Maisonneuve P (2006) Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20:197–209CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. 2008. CA Cancer J Clin 58:71–96CrossRefPubMedGoogle Scholar
  3. 3.
    Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369:1742–1757CrossRefPubMedGoogle Scholar
  4. 4.
    Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL (2000) Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18:43–56CrossRefPubMedGoogle Scholar
  5. 5.
    Maki JM, Tikkanen H, Kivirikko KI (2001) Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains. Matrix Biol 20:493–496CrossRefPubMedGoogle Scholar
  6. 6.
    Molnar J, Fong KS, He QP, Hayashi K, Kim Y, Fong SF, Fogelgren B, Szauter KM, Mink M, Csiszar K (2003) Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 1647:220–224PubMedGoogle Scholar
  7. 7.
    Smith-Mungo LI, Kagan HM (1998) Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 16:387–398CrossRefPubMedGoogle Scholar
  8. 8.
    Payne SL, Hendrix MJ, Kirschmann DA (2007) Paradoxical roles for lysyl oxidases in cancer—a prospect. J Cell Biochem 101:1338–1354CrossRefPubMedGoogle Scholar
  9. 9.
    Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M, Neufeld G (2003) Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res 63:1657–1666PubMedGoogle Scholar
  10. 10.
    Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ (2002) A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62:4478–4483PubMedGoogle Scholar
  11. 11.
    Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG (2007) Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 13:4769–4776CrossRefPubMedGoogle Scholar
  12. 12.
    Ban S, Ishikawa K, Kawai S, Koyama-Saegusa K, Ishikawa A, Shimada Y, Inazawa J, Imai T (2005) Potential in a single cancer cell to produce heterogeneous morphology, radiosensitivity and gene expression. J Radiat Res (Tokyo) 46:43–50CrossRefGoogle Scholar
  13. 13.
    Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, Parker MI, Csiszar K (2007) Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer 46:644–655CrossRefPubMedGoogle Scholar
  14. 14.
    Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, Mendiola M, de Diego JI, Nistal M, Quintanilla M, Portillo F, Cano A (2008) Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 68:4541–4550CrossRefPubMedGoogle Scholar
  15. 15.
    Grutzmann R, Foerder M, Alldinger I, Staub E, Brummendorf T, Ropcke S, Li X, Kristiansen G, Jesnowski R, Sipos B, Lohr M, Luttges J, Ockert D, Kloppel G, Saeger HD, Pilarsky C (2003) Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 443:508–517CrossRefPubMedGoogle Scholar
  16. 16.
    Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A, Pandey A (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5:157–171PubMedGoogle Scholar
  17. 17.
    Pilarsky C, Ammerpohl O, Sipos B, Dahl E, Hartmann A, Wellmann A, Braunschweig T, Lohr M, Jesnowski R, Friess H, Wente MN, Kristiansen G, Jahnke B, Denz A, Ruckert F, Schackert HK, Kloppel G, Kalthoff H, Saeger HD, Grutzmann R (2008) Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med 12:2823–2835CrossRefPubMedGoogle Scholar
  18. 18.
    Barrallo-Gimeno A, Nieto MA (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161CrossRefPubMedGoogle Scholar
  19. 19.
    Peinado H, Portillo F, Cano A (2005) Switching on-off snail: LOXL2 versus GSK3beta. Cell Cycle 4:1749–1752PubMedGoogle Scholar
  20. 20.
    Peinado H, Iglesias-de DC, la Cruz M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A, Portillo F (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. Embo J 24:3446–3458CrossRefPubMedGoogle Scholar
  21. 21.
    Jesnowski R, Furst D, Ringel J, Chen Y, Schrodel A, Kleeff J, Kolb A, Schareck WD, Lohr M (2005) Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest 85:1276–1291CrossRefPubMedGoogle Scholar
  22. 22.
    Grutzmann R, Pilarsky C, Ammerpohl O, Luttges J, Bohme A, Sipos B, Foerder M, Alldinger I, Jahnke B, Schackert HK, Kalthoff H, Kremer B, Kloppel G, Saeger HD (2004) Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6:611–622CrossRefPubMedGoogle Scholar
  23. 23.
    Madden ME, Sarras MP Jr (1988) Morphological and biochemical characterization of a human pancreatic ductal cell line (PANC-1). Pancreas 3:512–528CrossRefPubMedGoogle Scholar
  24. 24.
    Madden ME, Heaton KM, Huff JK, Sarras MP Jr (1989) Comparative analysis of a human pancreatic undifferentiated cell line (MIA PaCa-2) to acinar and ductal cells. Pancreas 4:529–537PubMedCrossRefGoogle Scholar
  25. 25.
    Lo M, Ling V, Wang YZ, Gout PW (2008) The xc-cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99:464–472CrossRefPubMedGoogle Scholar
  26. 26.
    Wang C, Xiao Y, Hu Z, Chen Y, Liu N, Hu G (2008) PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett 582:2793–2798CrossRefPubMedGoogle Scholar
  27. 27.
    Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, Yamaoka Y, Nakamura Y (2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63:3043–3048PubMedGoogle Scholar
  28. 28.
    Stevens TH, Forgac M (1997) Structure, function and regulation of the vacuolar (H+)-ATPase. Annu Rev Cell Dev Biol 13:779–808CrossRefPubMedGoogle Scholar
  29. 29.
    Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R (2004) Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452CrossRefPubMedGoogle Scholar
  30. 30.
    Sennoune SR, Luo D, Martinez-Zaguilan R (2004) Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys 40:185–206CrossRefPubMedGoogle Scholar
  31. 31.
    King LM, Francomano CA (2001) Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics 71:163–173CrossRefPubMedGoogle Scholar
  32. 32.
    Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA (2007) Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 43:415–432CrossRefPubMedGoogle Scholar
  33. 33.
    Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61:7388–7393PubMedGoogle Scholar
  34. 34.
    Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS (2004) Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. Clin Cancer Res 10:708–717CrossRefPubMedGoogle Scholar
  35. 35.
    Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P (2008) Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134:365–372CrossRefPubMedGoogle Scholar
  36. 36.
    Mujoomdar M, Bennett A, Hoskin D, Blay J (2004) Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro. J Cell Physiol 201:429–438CrossRefPubMedGoogle Scholar
  37. 37.
    McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36:184–194CrossRefPubMedGoogle Scholar
  38. 38.
    Malo M, Charriere-Bertrand C, Chettaoui C, Fabre-Guillevin E, Maquerlot F, Lackmy A, Vallee B, Delaplace F, Barlovatz-Meimon G (2006) The PAI-1 swing: microenvironment and cancer cell migration. C R Biol 329:919–927CrossRefPubMedGoogle Scholar
  39. 39.
    Czekay RP, Loskutoff DJ (2004) Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229:1090–1096Google Scholar
  40. 40.
    Maiti B, Li J, de Bruin A, Gordon F, Timmers C, Opavsky R, Patil K, Tuttle J, Cleghorn W, Leone G (2005) Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem 280:18211–18220CrossRefPubMedGoogle Scholar
  41. 41.
    Le Cam L, Polanowska J, Fabbrizio E, Olivier M, Philips A, Ng Eaton E, Classon M, Geng Y, Sardet C (1999) Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. Embo J 18:1878–1890CrossRefPubMedGoogle Scholar
  42. 42.
    Chen CR, Kang Y, Siegel PM, Massague J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110:19–32CrossRefPubMedGoogle Scholar
  43. 43.
    Valladares A, Hernandez NG, Gomez FS, Curiel-Quezada E, Madrigal-Bujaidar E, Vergara MD, Martinez MS, Arenas Aranda DJ (2006) Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 170:147–151CrossRefPubMedGoogle Scholar
  44. 44.
    Wang A, Li CJ, Reddy PV, Pardee AB (2005) Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation. Cancer Res 65:7809–7814PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Felix Rückert
    • 1
  • Peer Joensson
    • 2
  • Hans-Detlev Saeger
    • 1
  • Robert Grützmann
    • 1
  • Christian Pilarsky
    • 1
  1. 1.Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav CarusTechnical University DresdenDresdenGermany
  2. 2.Department of Surgery ICharité-Medical School, Campus Benjamin FranklinBerlinGermany

Personalised recommendations